{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T05:28:31Z","timestamp":1794202111736,"version":"4.8.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>For most people living with HIV (PLWH), treatment with effective antiretroviral therapy (ART) results in suppression of viremia below the limit of detection of clinical assays, immune reconstitution, reduced immune activation, avoidance of opportunistic infections, and progression to AIDS. However, ART alone is not curative, and HIV persists in a non-replicating, latent form. In this review, we provide a historical perspective on non-specific latency reversal approaches (LRA 1.0) and summarize recent advances in latency reversal strategies that target specific signaling pathways within CD4+ T cells or other immune cells to induce expression of latent HIV (immune-based latency reversal, or LRA 2.0).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>The HIV reservoir is primarily composed of latently infected CD4+ T cells carrying integrated, replication-competent provirus that can give rise to rebound viremia if ART is stopped. Myeloid lineage cells also contribute to HIV latency in certain tissues; we focus here on CD4+ T cells as a sufficient body of evidence regarding latency reversal in myeloid cells is lacking. The immunomodulatory LRA 2.0 approaches we describe include pattern recognition receptor agonists, immune checkpoint inhibitors, non-canonical NF-kB stimulation, and transient CD8+ lymphocyte depletion, along with promising combination strategies. We highlight recent studies demonstrating robust latency reversal in nonhuman primate models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>While significant strides have been made in terms of virus reactivation from latency, initial hopes for latency reversal alone to result in a reduction of infected cells, through viral cytopathic effect or an unboosted immune system, have not been realized and it seems clear that even effective latency reversal strategies will need to be paired with an approach that facilitates immune recognition and clearance of cells containing reactivated virus.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11904-020-00540-z","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T11:03:30Z","timestamp":1610535810000},"page":"117-127","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Latency Reversal 2.0: Giving the Immune System a Seat at the Table"],"prefix":"10.1007","volume":"18","author":[{"given":"Vidisha","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Dashti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Mavigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7479-9546","authenticated-orcid":false,"given":"Ann","family":"Chahroudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"key":"540_CR1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/9498","volume":"5","author":"TW Chun","year":"1999","unstructured":"Chun TW, Engel D, Mizell SB, Hallahan CW, Fischette M, Park S, et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med. 1999;5:651\u20135.","journal-title":"Nat Med"},{"key":"540_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1086\/338123","volume":"185","author":"M Dybul","year":"2002","unstructured":"Dybul M, Hidalgo B, Chun TW, Belson M, Migueles SA, Justement JS, et al. Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. J Infect Dis. 2002;185:61\u20138.","journal-title":"J Infect Dis"},{"key":"540_CR3","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1097\/00002030-199912030-00012","volume":"13","author":"JM Prins","year":"1999","unstructured":"Prins JM, Jurriaans S, van Praag RM, Blaak H, van Rij R, Schellekens PT, et al. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS. 1999;13:2405\u201310.","journal-title":"AIDS"},{"key":"540_CR4","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1023\/A:1011091300321","volume":"21","author":"RM van Praag","year":"2001","unstructured":"van Praag RM, Prins JM, Roos MT, Schellekens PT, Ten Berge IJ, Yong SL, et al. OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol. 2001;21:218\u201326.","journal-title":"J Clin Immunol"},{"key":"540_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S0140-6736(05)67098-5","volume":"366","author":"G Lehrman","year":"2005","unstructured":"Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005;366:549\u201355.","journal-title":"Lancet"},{"key":"540_CR6","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1086\/511823","volume":"195","author":"JD Siliciano","year":"2007","unstructured":"Siliciano JD, Lai J, Callender M, Pitt E, Zhang H, Margolick JB, et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis. 2007;195:833\u20136.","journal-title":"J Infect Dis"},{"key":"540_CR7","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nature11286","volume":"487","author":"NM Archin","year":"2012","unstructured":"Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012;487:482\u20135.","journal-title":"Nature"},{"key":"540_CR8","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/infdis\/jiu155","volume":"210","author":"NM Archin","year":"2014","unstructured":"Archin NM, Bateson R, Tripathy MK, Crooks AM, Yang KH, Dahl NP, et al. HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. J Infect Dis. 2014;210:728\u201335.","journal-title":"J Infect Dis"},{"key":"540_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004473","volume":"10","author":"JH Elliott","year":"2014","unstructured":"Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog. 2014;10:e1004473.","journal-title":"PLoS Pathog"},{"key":"540_CR10","first-page":"E3413","volume":"113","author":"H Li","year":"2016","unstructured":"Li H, Wang S, Kong R, Ding W, Lee FH, Parker Z, et al. Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proc Natl Acad Sci U S A. 2016;113:E3413\u201322.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"540_CR11","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.1128\/JCM.41.10.4531-4536.2003","volume":"41","author":"S Palmer","year":"2003","unstructured":"Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2003;41:4531\u20136.","journal-title":"J Clin Microbiol"},{"key":"540_CR12","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1089\/aid.2018.0075","volume":"34","author":"AE Swanstrom","year":"2018","unstructured":"Swanstrom AE, Gorelick RJ, Wu G, Howell B, Vijayagopalan A, Shoemaker R, et al. Ultrasensitive immunoassay for simian immunodeficiency virus p27(CA). AIDS Res Hum Retrovir. 2018;34:993\u20131001.","journal-title":"AIDS Res Hum Retrovir"},{"key":"540_CR13","doi-asserted-by":"publisher","first-page":"7078","DOI":"10.1073\/pnas.1402873111","volume":"111","author":"AR Cillo","year":"2014","unstructured":"Cillo AR, Sobolewski MD, Bosch RJ, Fyne E, Piatak M Jr, Coffin JM, et al. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A. 2014;111:7078\u201383.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"540_CR14","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1093\/infdis\/jis502","volume":"206","author":"AO Pasternak","year":"2012","unstructured":"Pasternak AO, de Bruin M, Jurriaans S, Bakker M, Berkhout B, Prins JM, et al. Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma. J Infect Dis. 2012;206:1443\u201352.","journal-title":"J Infect Dis"},{"key":"540_CR15","doi-asserted-by":"crossref","unstructured":"Yukl SA, Kaiser P, Kim P, Telwatte S, Joshi SK, Vu M, et al. HIV latency in isolated patient CD4(+) T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing. Sci Transl Med. 2018;10.","DOI":"10.1126\/scitranslmed.aap9927"},{"key":"540_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nm.3489","volume":"20","author":"CK Bullen","year":"2014","unstructured":"Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med. 2014;20:425\u20139.","journal-title":"Nat Med"},{"key":"540_CR17","doi-asserted-by":"publisher","first-page":"113778","DOI":"10.1016\/j.jviromet.2019.113778","volume":"276","author":"A Bertoldi","year":"2020","unstructured":"Bertoldi A, D\u2019Urbano V, Bon I, Verbon A, Rokx C, Boucher C, et al. Development of C-TILDA: a modified TILDA method for reservoir quantification in long term treated patients infected with subtype C HIV-1. J Virol Methods. 2020;276:113778.","journal-title":"J Virol Methods"},{"key":"540_CR18","doi-asserted-by":"publisher","first-page":"12078","DOI":"10.1038\/s41598-019-48354-3","volume":"9","author":"I Frank","year":"2019","unstructured":"Frank I, Acharya A, Routhu NK, Aravantinou M, Harper JL, Maldonado S, et al. A tat\/rev induced limiting dilution assay to measure viral reservoirs in non-human primate models of HIV infection. Sci Rep. 2019;9:12078.","journal-title":"Sci Rep"},{"key":"540_CR19","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.ebiom.2015.06.019","volume":"2","author":"FA Procopio","year":"2015","unstructured":"Procopio FA, Fromentin R, Kulpa DA, Brehm JH, Bebin AG, Strain MC, et al. A novel assay to measure the magnitude of the inducible viral reservoir in HIV-infected individuals. EBioMedicine. 2015;2:874\u201383.","journal-title":"EBioMedicine"},{"key":"540_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12977-017-0387-9","volume":"15","author":"C Deleage","year":"2018","unstructured":"Deleage C, Chan CN, Busman-Sahay K, Estes JD. Next-generation in situ hybridization approaches to define and quantify HIV and SIV reservoirs in tissue microenvironments. Retrovirology. 2018;15:4.","journal-title":"Retrovirology"},{"key":"540_CR21","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.3389\/fmicb.2018.02358","volume":"9","author":"W Zhang","year":"2018","unstructured":"Zhang W, Svensson Akusjarvi S, Sonnerborg A, Neogi U. Characterization of inducible transcription and translation-competent HIV-1 using the RNAscope ISH technology at a single-cell resolution. Front Microbiol. 2018;9:2358.","journal-title":"Front Microbiol"},{"key":"540_CR22","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1038\/nprot.2017.079","volume":"12","author":"AE Baxter","year":"2017","unstructured":"Baxter AE, Niessl J, Fromentin R, Richard J, Porichis F, Massanella M, et al. Multiparametric characterization of rare HIV-infected cells using an RNA-flow FISH technique. Nat Protoc. 2017;12:2029\u201349.","journal-title":"Nat Protoc"},{"key":"540_CR23","doi-asserted-by":"publisher","first-page":"9018","DOI":"10.1128\/JVI.01448-16","volume":"90","author":"G Martrus","year":"2016","unstructured":"Martrus G, Niehrs A, Cornelis R, Rechtien A, Garcia-Beltran W, Lutgehetmann M, et al. Kinetics of HIV-1 latency reversal quantified on the single-cell level using a novel flow-based technique. J Virol. 2016;90:9018\u201328.","journal-title":"J Virol"},{"key":"540_CR24","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/S2352-3018(14)70014-1","volume":"1","author":"TA Rasmussen","year":"2014","unstructured":"Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1\/2, single group, clinical trial. Lancet HIV. 2014;1:e13\u201321.","journal-title":"Lancet HIV"},{"key":"540_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005142","volume":"11","author":"OS Sogaard","year":"2015","unstructured":"Sogaard OS, Graversen ME, Leth S, Olesen R, Brinkmann CR, Nissen SK, et al. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog. 2015;11:e1005142.","journal-title":"PLoS Pathog"},{"key":"540_CR26","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1097\/QAD.0b013e32835535f5","volume":"26","author":"S Bouchat","year":"2012","unstructured":"Bouchat S, Gatot JS, Kabeya K, Cardona C, Colin L, Herbein G, et al. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients. AIDS. 2012;26:1473\u201382.","journal-title":"AIDS"},{"key":"540_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/nar\/gks976","volume":"41","author":"Z Li","year":"2013","unstructured":"Li Z, Guo J, Wu Y, Zhou Q. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res. 2013;41:277\u201387.","journal-title":"Nucleic Acids Res"},{"key":"540_CR28","doi-asserted-by":"publisher","first-page":"16646","DOI":"10.1038\/s41598-017-16816-1","volume":"7","author":"P Lu","year":"2017","unstructured":"Lu P, Shen Y, Yang H, Wang Y, Jiang Z, Yang X, et al. BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency. Sci Rep. 2017;7:16646.","journal-title":"Sci Rep"},{"key":"540_CR29","doi-asserted-by":"crossref","unstructured":"\u2022 Lim SY, Osuna CE, Hraber PT, Hesselgesser J, Gerold JM, Barnes TL, et al. TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy. Sci Transl Med. 2018;10 This work showed that TLR7 agonist (GS-986 and GS-9620) treatment induced upregulation of antiviral genes, transient on-ART viremia, and reduction in the viral reservoir size in SIV-infected macaques.","DOI":"10.1126\/scitranslmed.aao4521"},{"key":"540_CR30","doi-asserted-by":"crossref","unstructured":"\u2022 Del Prete GQ, Alvord WG, Li Y, Deleage C, Nag M, Oswald K, et al. TLR7 agonist administration to SIV-infected macaques receiving early initiated cART does not induce plasma viremia. JCI Insight. 2019;4 This study demonstrated that repeat dosing of the TLR7 agonist GS-9620 in SIV-infected macaques receiving early, long-term ART did not result in measurable increases in on-ART viremia suggesting that latency reversal with TLR-7 agonism could depend on the timing and duration of ART.","DOI":"10.1172\/jci.insight.127717"},{"key":"540_CR31","doi-asserted-by":"crossref","unstructured":"\u2022 Bekerman E, Hesselgesser J, Carr B, Nagel M, Hung M, Wang A, et al. PD-1 blockade and TLR7 activation lack therapeutic benefit in chronic simian immunodeficiency virus-infected macaques on antiretroviral therapy. Antimicrob Agents Chemother. 2019;63 Here, SIV-infected macaques initiated on ART during chronic infection and treated with the TLR7 agonist GS-9620 (or GS-9620 plus PD-1 blockade) did not have evidence of on-ART viremia nor a difference in viral reservoir size and viral rebound kinetics after ART interruption compared to control macaques.","DOI":"10.1128\/AAC.01163-19"},{"key":"540_CR32","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nature20583","volume":"540","author":"EN Borducchi","year":"2016","unstructured":"\u2022 Borducchi EN, Cabral C, Stephenson KE, Liu J, Abbink P, Ng\u2019ang\u2019a D, et al. Ad26\/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. Nature. 2016;540:284\u20137 In the first report of TLR-7 stimulation with GS-986 in SIV-infected, ART-suppressed macaques, there were no increases seen in on-ART viremia in the GS-986 only group. TLR-7 stimulation in combination with therapeutic vaccination did result in longer time to viral rebound and lower viral set point after ART interruption.","journal-title":"Nature"},{"key":"540_CR33","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41586-018-0600-6","volume":"563","author":"EN Borducchi","year":"2018","unstructured":"Borducchi EN, Liu J, Nkolola JP, Cadena AM, Yu WH, Fischinger S, et al. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature. 2018;563:360\u20134.","journal-title":"Nature"},{"key":"540_CR34","doi-asserted-by":"publisher","first-page":"e1008954","DOI":"10.1371\/journal.ppat.1008954","volume":"16","author":"K Bricker","year":"2020","unstructured":"Bricker K, Obregon-Perko V, Uddin F, Williams B, Uffmna EA, Garrido C, et al. (in press) Therapeutic vaccination of SIV-infected, ART-treated infant rhesus macaques using Ad48\/MVA in combination with TLR-7 stimulation. PLoS Pathog. 2020;16:e1008954.","journal-title":"PLoS Pathog"},{"key":"540_CR35","doi-asserted-by":"publisher","unstructured":"Riddler SA, Para M, Benson CA, Mills A, Ramgopal M, DeJesus E, et al. Vesatolimod, a toll-like receptor 7 agonist, induces immune activation in virally suppressed adults with HIV-1. Clin Infect Dis. 2020. https:\/\/doi.org\/10.1093\/cid\/ciaa1534.","DOI":"10.1093\/cid\/ciaa1534"},{"key":"540_CR36","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1093\/cid\/cix201","volume":"64","author":"L Vibholm","year":"2017","unstructured":"Vibholm L, Schleimann MH, Hojen JF, Benfield T, Offersen R, Rasmussen K, et al. Short-course toll-like receptor 9 agonist treatment impacts innate immunity and plasma viremia in individuals with human immunodeficiency virus infection. Clin Infect Dis. 2017;64:1686\u201395.","journal-title":"Clin Infect Dis"},{"key":"540_CR37","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1097\/QAD.0000000000002213","volume":"33","author":"LK Vibholm","year":"2019","unstructured":"Vibholm LK, Konrad CV, Schleimann MH, Frattari G, Winckelmann A, Klastrup V, et al. Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals. AIDS. 2019;33:1315\u201325.","journal-title":"AIDS"},{"key":"540_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062074","volume":"8","author":"AA Winckelmann","year":"2013","unstructured":"Winckelmann AA, Munk-Petersen LV, Rasmussen TA, Melchjorsen J, Hjelholt TJ, Montefiori D, et al. Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients. PLoS One. 2013;8:e62074.","journal-title":"PLoS One"},{"key":"540_CR39","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3389\/fimmu.2019.00725","volume":"10","author":"M Saxena","year":"2019","unstructured":"Saxena M, Sabado RL, La Mar M, Mohri H, Salazar AM, Dong H, et al. Poly-ICLC, a TLR3 agonist, induces transient innate immune responses in patients with treated HIV-infection: a randomized double-blinded placebo controlled trial. Front Immunol. 2019;10:725.","journal-title":"Front Immunol"},{"key":"540_CR40","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nm.4124","volume":"22","author":"P Li","year":"2016","unstructured":"Li P, Kaiser P, Lampiris HW, Kim P, Yukl SA, Havlir DV, et al. Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation. Nat Med. 2016;22:807\u201311.","journal-title":"Nat Med"},{"key":"540_CR41","doi-asserted-by":"publisher","first-page":"5917","DOI":"10.1038\/s41598-019-42253-3","volume":"9","author":"T Yamamoto","year":"2019","unstructured":"Yamamoto T, Kanuma T, Takahama S, Okamura T, Moriishi E, Ishii KJ, et al. STING agonists activate latently infected cells and enhance SIV-specific responses ex vivo in naturally SIV controlled cynomolgus macaques. Sci Rep. 2019;9:5917.","journal-title":"Sci Rep"},{"key":"540_CR42","doi-asserted-by":"crossref","unstructured":"Palermo E, Acchioni C, Di Carlo D, Zevini A, Muscolini M, Ferrari M, et al. Activation of latent HIV-1 T cell reservoirs with a combination of innate immune and epigenetic regulators. J Virol. 2019;93.","DOI":"10.1128\/JVI.01194-19"},{"key":"540_CR43","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nm.1972","volume":"15","author":"N Chomont","year":"2009","unstructured":"Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15:893\u2013900.","journal-title":"Nat Med"},{"key":"540_CR44","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1097\/QAD.0000000000001849","volume":"32","author":"VA Evans","year":"2018","unstructured":"Evans VA, van der Sluis RM, Solomon A, Dantanarayana A, McNeil C, Garsia R, et al. Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency. AIDS. 2018;32:1491\u20137.","journal-title":"AIDS"},{"key":"540_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005761","volume":"12","author":"R Fromentin","year":"2016","unstructured":"Fromentin R, Bakeman W, Lawani MB, Khoury G, Hartogensis W, DaFonseca S, et al. CD4+ T cells expressing PD-1, TIGIT and LAG-3 contribute to HIV persistence during ART. PLoS Pathog. 2016;12:e1005761.","journal-title":"PLoS Pathog"},{"issue":"776\u2013788","key":"540_CR46","volume":"47","author":"CS McGary","year":"2017","unstructured":"McGary CS, Deleage C, Harper J, Micci L, Ribeiro SP, Paganini S, et al. CTLA-4(+)PD-1(-) memory CD4(+) T cells critically contribute to viral persistence in antiretroviral therapy-suppressed, SIV-Infected Rhesus Macaques. Immunity. 2017;47(776\u2013788):e5.","journal-title":"Immunity"},{"issue":"2783\u20132795","key":"540_CR47","volume":"29","author":"M Pardons","year":"2019","unstructured":"Pardons M, Fromentin R, Pagliuzza A, Routy JP, Chomont N. Latency-reversing agents induce differential responses in distinct memory CD4 T cell subsets in individuals on antiretroviral therapy. Cell Rep. 2019;29(2783\u20132795):e5.","journal-title":"Cell Rep"},{"key":"540_CR48","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3389\/fimmu.2020.01223","volume":"11","author":"H Chen","year":"2020","unstructured":"Chen H, Moussa M, Catalfamo M. The role of immunomodulatory receptors in the pathogenesis of HIV infection: a therapeutic opportunity for HIV cure? Front Immunol. 2020;11:1223.","journal-title":"Front Immunol"},{"key":"540_CR49","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/QAD.0000000000000562","volume":"29","author":"F Wightman","year":"2015","unstructured":"Wightman F, Solomon A, Kumar SS, Urriola N, Gallagher K, Hiener B, et al. Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma. AIDS. 2015;29:504\u20136.","journal-title":"AIDS"},{"key":"540_CR50","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/annonc\/mdx696","volume":"29","author":"A Guihot","year":"2018","unstructured":"Guihot A, Marcelin AG, Massiani MA, Samri A, Soulie C, Autran B, et al. Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer. Ann Oncol. 2018;29:517\u20138.","journal-title":"Ann Oncol"},{"key":"540_CR51","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1097\/QAD.0000000000001429","volume":"31","author":"G Le Garff","year":"2017","unstructured":"Le Garff G, Samri A, Lambert-Niclot S, Even S, Lavole A, Cadranel J, et al. Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab. AIDS. 2017;31:1048\u201351.","journal-title":"AIDS"},{"key":"540_CR52","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1093\/annonc\/mdy259","volume":"29","author":"EP Scully","year":"2018","unstructured":"Scully EP, Rutishauser RL, Simoneau CR, Delagreverie H, Euler Z, Thanh C, et al. Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection. Ann Oncol. 2018;29:2141\u20132.","journal-title":"Ann Oncol"},{"key":"540_CR53","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41591-020-0782-y","volume":"26","author":"J Harper","year":"2020","unstructured":"\u2022\u2022 Harper J, Gordon S, Chan CN, Wang H, Lindemuth E, Galardi C, et al. CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption. Nat Med. 2020;26:519\u201328 This study demonstrated that in SIV-infected long-term ART-treated macaques, CTLA-4\/PD-1 blockade was more effective in inducing latency reversal and reducing integrated virus in CD4+ T cells compared to PD-1 monotherapy alone, but had limited impact on viral rebound after ART interruption.","journal-title":"Nat Med"},{"key":"540_CR54","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/S0140-6736(04)17481-3","volume":"364","author":"MA Connolly","year":"2004","unstructured":"Connolly MA, Gayer M, Ryan MJ, Salama P, Spiegel P, Heymann DL. Communicable diseases in complex emergencies: impact and challenges. Lancet. 2004;364:1974\u201383.","journal-title":"Lancet"},{"key":"540_CR55","unstructured":"Gay C, Hardy D. Safety and immunotherapeutic activity of an anti-PD-1 antibody (cemiplimab) in HIV-1-diagnosed participants on suppressive cART: a phase I\/II, double-blind, placebo-controlled, ascending multiple dose study, p. In (ed),"},{"key":"540_CR56","doi-asserted-by":"publisher","first-page":"6680","DOI":"10.1038\/sj.onc.1209954","volume":"25","author":"TD Gilmore","year":"2006","unstructured":"Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 2006;25:6680\u20134.","journal-title":"Oncogene"},{"key":"540_CR57","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nri.2017.52","volume":"17","author":"SC Sun","year":"2017","unstructured":"Sun SC. The non-canonical NF-kappaB pathway in immunity and inflammation. Nat Rev Immunol. 2017;17:545\u201358.","journal-title":"Nat Rev Immunol"},{"key":"540_CR58","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/cr.2010.177","volume":"21","author":"SC Sun","year":"2011","unstructured":"Sun SC. Non-canonical NF-kappaB signaling pathway. Cell Res. 2011;21:71\u201385.","journal-title":"Cell Res"},{"key":"540_CR59","doi-asserted-by":"publisher","first-page":"26243","DOI":"10.1074\/jbc.M403286200","volume":"279","author":"G Liao","year":"2004","unstructured":"Liao G, Zhang M, Harhaj EW, Sun SC. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem. 2004;279:26243\u201350.","journal-title":"J Biol Chem"},{"key":"540_CR60","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1097\/QAD.0000000000001064","volume":"30","author":"C Gutierrez","year":"2016","unstructured":"Gutierrez C, Serrano-Villar S, Madrid-Elena N, Perez-Elias MJ, Martin ME, Barbas C, et al. Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy. AIDS. 2016;30:1385\u201392.","journal-title":"AIDS"},{"key":"540_CR61","doi-asserted-by":"publisher","first-page":"e520","DOI":"10.1016\/S2352-3018(15)00226-X","volume":"2","author":"JH Elliott","year":"2015","unstructured":"Elliott JH, McMahon JH, Chang CC, Lee SA, Hartogensis W, Bumpus N, et al. Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV. 2015;2:e520\u20139.","journal-title":"Lancet HIV"},{"key":"540_CR62","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1093\/cid\/cit813","volume":"58","author":"AM Spivak","year":"2014","unstructured":"Spivak AM, Andrade A, Eisele E, Hoh R, Bacchetti P, Bumpus NN, et al. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis. 2014;58:883\u201390.","journal-title":"Clin Infect Dis"},{"key":"540_CR63","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.chom.2015.08.009","volume":"18","author":"L Pache","year":"2015","unstructured":"\u2022\u2022 Pache L, Dutra MS, Spivak AM, Marlett JM, Murry JP, Hwang Y, et al. BIRC2\/cIAP1 is a negative regulator of HIV-1 transcription and can be targeted by Smac mimetics to promote reversal of viral latency. Cell Host Microbe. 2015;18:345\u201353 This report first described the potential of SMACm to activate the ncNF-\u03baB pathway to reverse latency in several in vitro and ex vivo systems.","journal-title":"Cell Host Microbe"},{"key":"540_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211746","volume":"14","author":"M Bobardt","year":"2019","unstructured":"Bobardt M, Kuo J, Chatterji U, Chanda S, Little SJ, Wiedemann N, et al. The inhibitor apoptosis protein antagonist Debio 1143 is an attractive HIV-1 latency reversal candidate. PLoS One. 2019;14:e0211746.","journal-title":"PLoS One"},{"key":"540_CR65","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Nixon CC, Mavigner M, Sampey GC, Brooks AD, Spagnuolo RA, Irlbeck DM, et al. Systemic HIV and SIV latency reversal via non-canonical NF-kappaB signalling in vivo. Nature. 2020. https:\/\/doi.org\/10.1038\/s41586-020-1951-3This study demonstrated, in two complementary animal models, that in vivo treatment with the SMACm AZD5582 induced significant latency reversal measured by increases in HIV\/SIV RNA in plasma and in resting CD4+ T cells with minimal side effects.","DOI":"10.1038\/s41586-020-1951-3"},{"key":"540_CR66","doi-asserted-by":"publisher","first-page":"100037","DOI":"10.1016\/j.xcrm.2020.100037","volume":"1","author":"L Pache","year":"2020","unstructured":"Pache L, Marsden MD, Teriete P, Portillo AJ, Heimann D, Kim JT, et al. Pharmacological activation of non-canonical NF-\u03baB signaling activates latent HIV-1 reservoirs in vivo. Cell Reports Medicine. 2020;1:100037.","journal-title":"Cell Reports Medicine"},{"issue":"689\u2013702","key":"540_CR67","volume":"24","author":"GR Campbell","year":"2018","unstructured":"Campbell GR, Bruckman RS, Chu YL, Trout RN, Spector SA. SMAC Mimetics induce autophagy-dependent apoptosis of HIV-1-infected resting memory CD4+ T cells. Cell Host Microbe. 2018;24(689\u2013702):e7.","journal-title":"Cell Host Microbe"},{"key":"540_CR68","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41419-020-02761-x","volume":"11","author":"GR Campbell","year":"2020","unstructured":"Campbell GR, To RK, Zhang G, Spector SA. SMAC mimetics induce autophagy-dependent apoptosis of HIV-1-infected macrophages. Cell Death Dis. 2020;11:590.","journal-title":"Cell Death Dis"},{"key":"540_CR69","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1126\/science.2431484","volume":"234","author":"CM Walker","year":"1986","unstructured":"Walker CM, Moody DJ, Stites DP, Levy JA. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science. 1986;234:1563\u20136.","journal-title":"Science"},{"key":"540_CR70","doi-asserted-by":"crossref","unstructured":"McBrien JB, Wong AKH, White E, Carnathan DG, Lee JH, Safrit JT, et al. Combination of CD8beta depletion and interleukin-15 superagonist N-803 induces virus reactivation in simian-human immunodeficiency virus-infected, long-term ART-treated rhesus macaques. J Virol. 2020;94.","DOI":"10.1128\/JVI.00755-20"},{"key":"540_CR71","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.immuni.2016.08.018","volume":"45","author":"EK Cartwright","year":"2016","unstructured":"Cartwright EK, Spicer L, Smith SA, Lee D, Fast R, Paganini S, et al. CD8(+) lymphocytes are required for maintaining viral suppression in SIV-infected macaques treated with short-term antiretroviral therapy. Immunity. 2016;45:656\u201368.","journal-title":"Immunity"},{"key":"540_CR72","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 McBrien JB, Mavigner M, Franchitti L, Smith SA, White E, Tharp GK, et al. Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8(+) cells. Nature. 2020. https:\/\/doi.org\/10.1038\/s41586-020-1946-0Using multiple models, this work demonstrated robust latency reversal evidenced by prolonged on-ART viremia with the IL-15 superagonist N-803 in combination with depletion of CD8\u03b1 expresing lymphocytes. This LRA combination induced significantly greater and more persistent viremia than either agent alone further highlighting the role of CD8+ cells in suppressing virus reactivation.","DOI":"10.1038\/s41586-020-1946-0"},{"key":"540_CR73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005545","volume":"12","author":"RB Jones","year":"2016","unstructured":"Jones RB, Mueller S, O\u2019Connor R, Rimpel K, Sloan DD, Karel D, et al. A subset of latency-reversing agents expose HIV-infected resting CD4+ T-cells to recognition by cytotoxic T-lymphocytes. PLoS Pathog. 2016;12:e1005545.","journal-title":"PLoS Pathog"},{"key":"540_CR74","volume-title":"CD8 lymphocyte depletion enhances the latency reversal activity of the SMAC mimetic AZD5582 in ART-suppressed SIV-infected rhesus macaques JVI [under review]","author":"M Mavigner","year":"2020","unstructured":"Mavigner M, Liao L, Brooks A, Ke R, Mattingly C, Schoof N, Liang S, Vanderford T, Paiardini M, Kulpa D, Lifson J, Dunham R, Margolis D, Perelson A, Silvestri G, Chahroudi A. 2020. CD8 lymphocyte depletion enhances the latency reversal activity of the SMAC mimetic AZD5582 in ART-suppressed SIV-infected rhesus macaques JVI [under review]."},{"key":"540_CR75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008821","volume":"16","author":"M Zanoni","year":"2020","unstructured":"Zanoni M, Palesch D, Pinacchio C, Statzu M, Tharp GK, Paiardini M, et al. Innate, non-cytolytic CD8+ T cell-mediated suppression of HIV replication by MHC-independent inhibition of virus transcription. PLoS Pathog. 2020;16:e1008821.","journal-title":"PLoS Pathog"},{"key":"540_CR76","doi-asserted-by":"crossref","unstructured":"Macedo AB, Novis CL, De Assis CM, Sorensen ES, Moszczynski P, Huang SH, et al. Dual TLR2 and TLR7 agonists as HIV latency-reversing agents. JCI Insight. 2018;3.","DOI":"10.1172\/jci.insight.122673"},{"key":"540_CR77","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.4049\/jimmunol.1003174","volume":"186","author":"E Schlaepfer","year":"2011","unstructured":"Schlaepfer E, Speck RF. TLR8 activates HIV from latently infected cells of myeloid-monocytic origin directly via the MAPK pathway and from latently infected CD4+ T cells indirectly via TNF-alpha. J Immunol. 2011;186:4314\u201324.","journal-title":"J Immunol"},{"key":"540_CR78","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/1742-4690-10-119","volume":"10","author":"CL Novis","year":"2013","unstructured":"Novis CL, Archin NM, Buzon MJ, Verdin E, Round JL, Lichterfeld M, et al. Reactivation of latent HIV-1 in central memory CD4(+) T cells through TLR-1\/2 stimulation. Retrovirology. 2013;10:119.","journal-title":"Retrovirology"},{"key":"540_CR79","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S2055-6640(20)30042-X","volume":"5","author":"JD Gunst","year":"2019","unstructured":"Gunst JD, Kjaer K, Olesen R, Rasmussen TA, Ostergaard L, Denton PW, et al. Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation. J Virus Erad. 2019;5:133\u20137.","journal-title":"J Virus Erad"},{"key":"540_CR80","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.celrep.2017.01.022","volume":"18","author":"A Bosque","year":"2017","unstructured":"Bosque A, Nilson KA, Macedo AB, Spivak AM, Archin NM, Van Wagoner RM, et al. Benzotriazoles reactivate latent HIV-1 through inactivation of STAT5 SUMOylation. Cell Rep. 2017;18:1324\u201334.","journal-title":"Cell Rep"},{"key":"540_CR81","first-page":"202","volume":"21","author":"A Chahroudi","year":"2010","unstructured":"Chahroudi A, Silvestri G. Interleukin-7 in HIV pathogenesis and therapy. Eur Cytokine Netw. 2010;21:202\u20137.","journal-title":"Eur Cytokine Netw"},{"key":"540_CR82","unstructured":"Anonymous. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=N803&cntry=&state=&city=&dist=. Accessed."},{"key":"540_CR83","doi-asserted-by":"publisher","first-page":"13077","DOI":"10.1128\/JVI.76.24.13077-13082.2002","volume":"76","author":"DD Scripture-Adams","year":"2002","unstructured":"Scripture-Adams DD, Brooks DG, Korin YD, Zack JA. Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol. 2002;76:13077\u201382.","journal-title":"J Virol"},{"key":"540_CR84","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/nrd.2017.116","volume":"16","author":"BG Childs","year":"2017","unstructured":"Childs BG, Gluscevic M, Baker DJ, Laberge RM, Marquess D, Dananberg J, et al. Senescent cells: an emerging target for diseases of ageing. Nat Rev Drug Discov. 2017;16:718\u201335.","journal-title":"Nat Rev Drug Discov"},{"key":"540_CR85","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/j.1474-9726.2012.00856.x","volume":"11","author":"JA Nelson","year":"2012","unstructured":"Nelson JA, Krishnamurthy J, Menezes P, Liu Y, Hudgens MG, Sharpless NE, et al. Expression of p16(INK4a) as a biomarker of T-cell aging in HIV-infected patients prior to and during antiretroviral therapy. Aging Cell. 2012;11:916\u20138.","journal-title":"Aging Cell"},{"key":"540_CR86","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s11904-020-00496-0","volume":"17","author":"MA Szaniawski","year":"2020","unstructured":"Szaniawski MA, Spivak AM. Senotherapeutics and HIV-1 persistence. Curr HIV\/AIDS Rep. 2020;17:219\u201325.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"540_CR87","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1172\/JCI89552","volume":"127","author":"AR Martin","year":"2017","unstructured":"Martin AR, Pollack RA, Capoferri A, Ambinder RF, Durand CM, Siliciano RF. Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity. J Clin Invest. 2017;127:651\u20136.","journal-title":"J Clin Invest"},{"key":"540_CR88","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12977-016-0319-0","volume":"13","author":"AM Spivak","year":"2016","unstructured":"Spivak AM, Larragoite ET, Coletti ML, Macedo AB, Martins LJ, Bosque A, et al. Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo. Retrovirology. 2016;13:88.","journal-title":"Retrovirology"},{"key":"540_CR89","doi-asserted-by":"publisher","unstructured":"Dashti A, Waller C, Mavigner M, Schoof N, Bar KJ, Shaw GM, et al. SMAC mimetic plus triple combination bispecific HIVxCD3 DART(R) molecules in SHIV.C.CH505-infected, ART-suppressed rhesus macaques. J Virol. 2020. https:\/\/doi.org\/10.1128\/JVI.00793-20.","DOI":"10.1128\/JVI.00793-20"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-020-00540-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-020-00540-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-020-00540-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T03:44:41Z","timestamp":1674877481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-020-00540-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":89,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["540"],"URL":"https:\/\/doi.org\/10.1007\/s11904-020-00540-z","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,12]]},"assertion":[{"value":"21 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}